tiprankstipranks
Valneva Strengthens Board, Shareholders Back Plans
Company Announcements

Valneva Strengthens Board, Shareholders Back Plans

Valneva (VALN) has released an update.

Don't Miss Our Christmas Offers:

Valneva SE, a leading specialty vaccine company, announced the unanimous approval of all board-recommended resolutions at its Combined General Meeting, including the endorsement of the 2023 financial statements and the strategic appointment of Ms. Danièle Guyot-Caparros as a new director. Ms. Guyot-Caparros brings extensive finance and pharmaceutical industry experience to Valneva’s Board of Directors. The company, known for marketing the first chikungunya vaccine and developing the only advanced candidate for Lyme disease, reaffirms its commitment to addressing unmet medical needs with its specialized vaccine portfolio.

For further insights into VALN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskValneva and Serum Institute of India Collaborate to Tackle Chikungunya in Asia
TipRanks Auto-Generated NewsdeskValneva Highlights Chikungunya’s Global Economic Impact
TipRanks Auto-Generated NewsdeskValneva’s Chikungunya Vaccine Shows Long-Lasting Efficacy
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App